FPR1 and sarcoma: RI-3 adopts a turn structure very similar to that adopted by previous characterized uPAR-FPR1 antagonists, is stable in human serum, prevents the uPAR/FPR1 interaction and potently inhibits migration and invasion of human sarcoma and melanoma cells15,30,31,33,34.